MedPage Today on MSN6d
Better Response, Survival in Head and Neck Cancer With Dual Pre-Op ImmunotherapyTwo neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical ...
Chinese biotech Akeso (HKEX: 9926) has reported encouraging early data from a Phase III trial of its bispecific antibody ...
Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...
Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in ...
Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback